MESO
Mesoblast Limited
NASDAQ · Healthcare · Biotechnology · AU
$17.32
+1.05%Margins
Gross margin
79.7%
EBITDA margin
-37.3%
EBIT margin
-97.8%
Net margin
-47.6%
FCF margin
-35.1%
-10.1%
Return on equity
-7.4%
Return on assets
-17.0%
Return on invested capital
0.16x
Asset turnover
-$41.3M
Cash from operations
$0.79
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026